Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib
Checked against the public recordLast updated Jan 25, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Genzyme, a Sanofi Company
- Interventions being studied
- Drug: Vandetanib; Drug: Erlotinib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Confirmed locally advanced or metastatic NSCLC * Failure of at least one but not more than two prior chemotherapy regimens Exclusion Criteria: * Prior treatment with erlotinib (Tarceva), gefitinib (IRESSA), sunitinib (Sutent), sorafenib (Nexavar) * Chemotherapy or other type of anti cancer therapy within 4 weeks of study start
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Research SiteBerkeley, California
- Research SiteLos Angeles, California
- Research SiteSanta Rosa, California
- Research SiteBoynton Beach, Florida
- Research SiteFort Myers, Florida
- Research SiteJacksonville, Florida
- Research SitePort Saint Lucie, Florida
- Research SiteWichita, Kansas
- Research SiteLexington, Kentucky
- Research SiteLouisville, Kentucky
- Research SiteMetairie, Louisiana
- Research SiteBaltimore, Maryland
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 25, 2018. Always confirm current availability with the study team.